Corporate Presentation and Research Reports
Corporate Presentation
MediciNova Corporate Presentation – March 15, 2024
Zacks Research Reports
MNOV: Encouraging Phase 2 Glioblastoma Results Presented at SNO – November 27, 2023
MNOV: Expecting Data for MN-166 in GBM and Chlorine Gas-Induced Lung Injury – August 21, 2023
MNOV: Compelling Buying Opportunity in Differentiated Small-Cap Biotech – May 30, 2023
MNOV: Phase 1/2 Clinical Trial of MN-166 in GBM Fully Enrolled – February 27, 2023
MNOV: Well Financed to Get Through Tough Market Conditions – November 18, 2022
MNOV: Genzyme Patent Litigation Could Lead to Significant Payout – April 6, 2022
MNOV: Animal Trials Commence Testing MN-166 as an MCM – August 16, 2021
MNOV: Positive Results for MN-166 in Phase 2 AUD Trial – June 22, 2021
MNOV: Phase 3 ALS Trial Ongoing – May 28, 2021
MNOV: Milestone Payments from Legacy Gene Therapy Assets – April 26, 2021
MNOV: BARDA Contract to Support Development of MN-166 in ARDS – March 15, 2021
MNOV: $20M Investment to Fund Multiple Programs – January 25, 2021
MNOV: Multiple ‘Shots on Goal’ Provide Substantial Potential Upside – May 1, 2020
MNOV: Phase 3 Trial Initiated for MN-166 in ALS – October 30, 2019
MNOV: Abstract on MN-166 to be Presented at ALS/MND International Symposium – August 14, 2019